Application of the †5-2-1' screening criteria in advanced Parkinson's disease: Interim analysis of DUOGLOBE

Jason Aldred*, Marieta Anca-Herschkovitsch, Angelo Antonini, Ovidiu Bajenaru, Lars Bergmann, Paul Bourgeois, Esther Cubo, Thomas L. Davis, Robert Iansek, Norbert Kovács, Pavnit Kukreja, Koray Onuk, Francesco E. Pontieri, Weining Robieson, Mustafa S. Siddiqui, Mihaela Simu, David G. Standaert, K. Ray Chaudhuri

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)


Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the †5-2-1 criteria' (≥five-times daily oral levodopa use, ≥two daily hours with †Off' symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson's disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD-a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE)-is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa-carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.

Original languageEnglish
Pages (from-to)309-323
Number of pages15
JournalNeurodegenerative Disease Management
Issue number5
Publication statusPublished - Oct 2020


  • 5-2-1
  • criteria for advanced PD
  • dyskinesia
  • LCIG
  • levodopa
  • levodopa-carbidopa intestinal gel
  • off time
  • Parkinson's disease


Dive into the research topics of 'Application of the †5-2-1' screening criteria in advanced Parkinson's disease: Interim analysis of DUOGLOBE'. Together they form a unique fingerprint.

Cite this